Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy

NCT01094405 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancer
Epstein-Barr Virus Infections

Interventions

BIOLOGICAL: Recombinant Epstein-Barr Virus (EBV) Vaccine

Sponsor

Chinese University of Hong Kong